HCMHutchmedSigning up patients
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Solid Tumors, Adult
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 186 (planned)
- Started
- Mar 4, 2026
- Main results expected
- Dec 31, 2028
- Fully finished
- Jan 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Tolerated Dose (MTD) and/or recommended dose(s) for expansion(RDE)
Measured over: Approximately 12 months
Overview of Treatment-emergent Adverse Events (TEAEs)
Measured over: Approximately 12 months
Objective Response Rate (ORR)
Measured over: At least 8 weeks post dose of first participant up to approximately 24 months
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A580
Measured over: Approximately 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07396584 · record last updated 2026-09-18 · checked 2026-11-09 15:42 UTC